Efficacy and safety of FLOT combined with apatinib and sintilimab as a neoadjuvant therapy regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma: An open-lable, single-arm, phase II study

被引：1

作者：

Zhou, H. ^{[1
]}

Long, B. ^{[2
]}

Yu, Z. ^{[3
]}

Zhu, J. ^{[2
]}

Yang, H. ^{[4
]}

Zhang, W. ^{[3
]}

Guan, X. ^{[5
]}

Zhang, G. ^{[2
]}

Li, L. ^{[2
]}

Luo, C. ^{[2
]}

Cao, H. ^{[2
]}

Zhang, S. ^{[2
]}

Chen, S. ^{[2
]}

He, Q. ^{[2
]}

Gan, S. ^{[2
]}

Zhou, L. ^{[2
]}

Jiang, X. ^{[2
]}

Shi, W.

Huang, Z. ^{[5
]}

Mao, J. ^{[2
]}

Dong, C. ^{[6
]}

Jiao, Z. ^{[2
]}

机构：

[1] Gansu Prov Canc Hosp, Dept Abdominal Surg, Lanzhou, Peoples R China

[2] Lanzhou Univ Second Hosp, Dept Gen Surg, Lanzhou, Peoples R China

[3] Lanzhou Univ Second Hosp, Dept Radiol, Lanzhou, Peoples R China

[4] Lanzhou Univ Second Hosp, Cuiying Cent Lab, Lanzhou, Peoples R China

[5] Lanzhou Univ Second Hosp, Dept Gastroenterol, Lanzhou, Peoples R China

[6] Lanzhou Univ Second Hosp, Dept Pathol, Lanzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.202

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-146

引用

页码：S66 / S67

页数：2

共 50 条

[31] Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study [J].

Li, Jin ;

Qin, Shukui ;

Wen, Lu ;

Wang, Junsheng ;

Deng, Wenying ;

Guo, Weijian ;

Jia, Tongfu ;

Jiang, Da ;

Zhang, Guifang ;

He, Yifu ;

Ba, Yi ;

Zhong, Haijun ;

Wang, Lin ;

Lin, Xiaoyan ;

Yang, Jianwei ;

Zhao, Jun ;

Bai, Yuxian ;

Wu, Xiangyuan ;

Gao, Feng ;

Sun, Guogui ;

Wu, Yongjuan ;

Ye, Feng ;

Wang, Qiong ;

Xie, Zhong ;

Yi, Tienan ;

Huang, Yong ;

Yu, Guohua ;

Lu, Lin ;

Yuan, Ying ;

Li, Wei ;

Liu, Likun ;

Sun, Yuping ;

Sun, Ying ;

Yin, Lifeng ;

Hou, Zhiguo .

BMC MEDICINE, 2023, 21 (01)

[32] Surufatinib plus sintilimab in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, single-center phase II trial. [J].

Zhang, Dong-Sheng ;

Liu, Fu-Rong ;

Lu, Yun-Xin ;

Bai, Bing ;

Zhang, Yang ;

Wang, Zhi-Qiang ;

Liu, Yu ;

Chen, Jian-Wen ;

Wang, Feng ;

Xu, Rui-Hua .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) :358-358

[33] Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy. [J].

Liu, Ning ;

Liu, Zimin ;

Zhou, Yanbing ;

Niu, Zhaojian ;

Jiang, Haitao ;

Zhu, Yingqian ;

Wang, Huiyun ;

Li, Xiaoxiao ;

Song, Shanai ;

Liu, Xiaodong ;

Li, Zequn ;

Zhao, Shufen .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[34] Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial [J].

Ding, Xuewei ;

Li, Bin ;

Xue, Qiang ;

Cai, Mingzhi ;

Cui, Jingli ;

Wang, Baogui ;

Ke, Bin ;

Zhang, Rupeng ;

Liang, Han .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[35] Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial [J].

Zhang, P. ;

Zhang, W. ;

Liu, X. ;

He, D. ;

Yang, K. ;

Gou, H. ;

Hu, J. .

ANNALS OF ONCOLOGY, 2024, 35 :S903-S903

[36] Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial [J].

Zheng, Yanan ;

Yang, Xiao ;

Yan, Chao ;

Feng, Runhua ;

Sah, Birendra Kumar ;

Yang, Zhongyin ;

Zhu, Zhenglun ;

Liu, Wentao ;

Xu, Wei ;

Ni, Zhentian ;

Beeharry, Maneesh Kumarsing ;

Hua, Zichen ;

Yan, Min ;

Zhu, Zhenggang ;

Li, Chen .

EUROPEAN JOURNAL OF CANCER, 2020, 130 :12-19

[37] Conversion therapy of concurrent chemoradiotherapy combined with tislelizumab for unresectable gastric or gastroesophageal junction adenocarcinoma: A prospective, single-arm, phase II trial [J].

Liu, D. ;

Yang, L. ;

Lu, K. ;

Zhao, Q. ;

Yu, J. ;

Liu, Y. ;

Chen, Q. ;

Liu, L. .

ANNALS OF ONCOLOGY, 2024, 35 :S173-S173

[38] Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma. [J].

Liu, Ying ;

Han, Guangsen ;

Li, Hongle ;

Zhao, Yuzhou ;

Zhuang, Jing ;

Wang, Gangcheng ;

Li, Baodong ;

Wang, Jinbang ;

Li, Zhimeng ;

Xia, Qingxin ;

Ma, Jie ;

Zhang, Chengjuan ;

Yu, Juan ;

Li, Ke ;

Xu, Shuning ;

Qiao, Lei ;

Kuang, Gaizhen ;

Li, Danyang .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[39] A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma [J].

Shi, Jin-Ming ;

Li, Ning ;

Jiang, Li-Ming ;

Yang, Lin ;

Wang, Shu-Lian ;

Song, Yong-Wen ;

Liu, Yue-Ping ;

Fang, Hui ;

Lu, Ning-Ning ;

Qi, Shu-Nan ;

Chen, Bo ;

Li, Ye-Xiong ;

Zhao, Dong-Bing ;

Tang, Yuan ;

Jin, Jing .

SCIENTIFIC REPORTS, 2024, 14 (01)

[40] Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study [J].

Chao Jing ;

Junyun Wang ;

Mingyue Zhu ;

Zhigang Bai ;

Baoyi Zhao ;

Jun Zhang ;

Jie Yin ;

Xiaobao Yang ;

Zongzhi Liu ;

Zhongtao Zhang ;

Wei Deng .

Cancer Immunology, Immunotherapy, 2022, 71 :2597-2608

← 1 2 3 4 5 →